International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"High intensity focused ultrasound serves as a salvage treatment for uterine arteriovenous fistula when uterine artery embolization fails and pregnancy outcomes: a case report and literature review.","authors":"Shanyu Huang, Mingzhu Ye, Xiaoxiao Xi, Waixing Li, Xiaogang Zhu, Xin Sun","doi":"10.1080/02656736.2025.2519347","DOIUrl":"10.1080/02656736.2025.2519347","url":null,"abstract":"<p><p>Uterine arteriovenous fistula (UAVF) is an abnormal connection formed between the branches of the uterine artery and the venous plexus, accounting for 1%-2% of all reproductive system and abdominal bleeding. In recent years, the incidence has been gradually increasing due to acquired causes such as uterine surgery and pregnancy. The common clinical symptom is painless and irregular vaginal bleeding, which can lead to hemorrhagic shock. There is no standardized and unified treatment for UAVF. At present, uterine artery embolization (UAE) is considered the first-choice treatment for UAVF in clinical practice, but it is prone to treatment failure due to various potential complications. HIFU, as a noninvasive treatment, is currently used in a limited number of cases for the treatment of UAVF, and a few literature reports have shown clinical effects after high-intensity focused ultrasound (HIFU) treatment. This paper reports a case that HIFU was successfully used to treat UAVF after the failure of UAE, and the patient successfully became pregnant, indicating that HIFU can be used as an alternative after the failure of UAE treatment for UAVF, without affecting subsequent pregnancy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519347"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A preliminary comparative study of three different microwave ablation methods for cystic-solid thyroid nodules.","authors":"Xiang-Rong Xie, Yu-Fan Wu, Geng-Biao Zhang, Dong-Ming Guo, Chuang-Yu Ma, Wei-Jian Luo, Jin-Mei Pan, Yan-Ping Wu, Hong-Hui Su","doi":"10.1080/02656736.2025.2557954","DOIUrl":"10.1080/02656736.2025.2557954","url":null,"abstract":"<p><strong>Objective: </strong>This preliminary comparative study assessed the effectiveness of three microwave ablation (MWA) techniques in managing cystic-solid thyroid nodules.</p><p><strong>Methods: </strong>Patients who underwent MWA from January 2018 to October 2021 at the Second Affiliated Hospital of Shantou University Medical College were divided into three groups: Simple Aspiration Group (SAG) (cyst fluid drained before direct ablation), Epinephrine Solution Immersion Group (ESIG) (cyst fluid drained followed by soaking in epinephrine), and High-Power Ablation Group (HPAG) (immediate high-power ablation after drainage). Twenty patients were retrospectively analyzed in each group, comparing intraoperative intracapsular bleeding, ablation time of cystic-solid nodules, 12th-month nodule volume reduction rate (VRR), preoperative cosmetic and symptom scores, and postoperative scores.</p><p><strong>Results: </strong>Significant differences were observed in intraoperative intracapsular rebleeding (≥50% cyst cavity volume) between ESIG and SAG (<i>p</i> = 0.029) and HPAG and SAG (<i>p</i> = 0.008), but not between ESIG and HPAG (<i>p</i> = 0.602). The ablation time for cystic-solid nodules was shorter in ESIG and HPAG compared to SAG (<i>p</i> = 0.003 and <i>p</i> = 0.006, respectively), with no significant difference between ESIG and HPAG (<i>p</i> = 0.689). However, the 12th-month outcomes-VRRs, symptom scores, and cosmetic scores-showed no statistical significance among the groups (<i>p</i> = 0.634, <i>p</i> = 0.329, and <i>p</i> = 0.717, respectively).</p><p><strong>Conclusion: </strong>ESIG and HPAG significantly reduced intraoperative intracapsular bleeding and ablation time of solid-cystic nodules compared with SAG, indicating enhanced procedural efficiency. Nevertheless, the long-term therapeutic outcomes (nodule shrinkage, symptom relief, and cosmesis) were similar across all methods. These findings underscore the potential of epinephrine immersion and high-power ablation in optimizing MWA for cystic-solid nodules.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2557954"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermal ablation versus surgical resection for follicular thyroid neoplasm: a multicenter study.","authors":"Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu","doi":"10.1080/02656736.2025.2539177","DOIUrl":"10.1080/02656736.2025.2539177","url":null,"abstract":"<p><strong>Objectives: </strong>To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Materials and methods: </strong>In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Results: </strong>As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all <i>p</i> < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all <i>p</i> > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, <i>p</i> = 0.31). Permanent hoarseness (8.1% [15/135], <i>p</i> < 0.001), permanent hypoparathyroidism (0.7% [1/135], <i>p</i> = 0.74), transient hypoparathyroidism (3.0% [4/135], <i>p</i> = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], <i>p</i> < 0.001) were encountered only in the SR group.</p><p><strong>Conclusion: </strong>There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2539177"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blocking Tim-3 enhances CD8⁺ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation.","authors":"Na Wu, Xinru Pei, Weiguo Cai, Xiaodie Ye, Wei Lu","doi":"10.1080/02656736.2025.2516502","DOIUrl":"https://doi.org/10.1080/02656736.2025.2516502","url":null,"abstract":"<p><strong>Background: </strong>Incomplete radiofrequency ablation (iRFA) for hepatocellular carcinoma (HCC) during radiofrequency ablation (RFA) may result in rapid progression of residual tumors and resistance to anti-PD-1 therapy. Research has demonstrated elevated T-cell immunoglobulin and mucin domain 3 (Tim-3) expression in CD8⁺ T cells in the peripheral blood of patients with HCC after RFA, leading to a diminished anti-tumor immune response. Therefore, this study examined the effectiveness of anti-Tim-3 therapy in treating residual tumors after iRFA and explored the underlying mechanisms.</p><p><strong>Methods: </strong>To examine the expression of Tim-3 in the residual tumors after iRFA for HCC in mice. Treat residual tumors with anti-αTim-3 and evaluate its efficacy. Transcriptomic sequencing was conducted on the residual tumors to explore the underlying mechanisms. Meanwhile, residual tumors were treated with a combination of anti-αTim-3 and anti-αPD-1 to evaluate efficacy.</p><p><strong>Results: </strong>This study demonstrated elevated Tim-3 expression in CD8⁺ T cells within residual tumors after iRFA. CD8⁺ T cells exhibit attenuated anti-tumor immune responses associated with accelerated tumor progression. Treatment with anti-αTim-3 impeded the advancement of residual tumors by enhancing CD8⁺ T cell infiltration and stimulating their anti-tumor activities. Furthermore, anti-αTim-3 therapy upregulated PD-1 expression in residual tumors. Combination therapy involving anti-αTim-3 and anti-αPD-1 elicited a robust anti-tumor immune response.</p><p><strong>Conclusions: </strong>Tim-3 expression is elevated in CD8⁺ T cells within residual tumors after iRFA, which contributed to their accelerated advancement. Anti-αTim-3 slows tumor progression by boosting CD8⁺ T cell anti-tumor activity and enhancing response to anti-αPD-1 treatment.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2516502"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway.","authors":"Guanhui Zhou, Bo Sun, Feng Zhang, Hongxiu Ji, Xuefeng Kan, Xiaoming Yang","doi":"10.1080/02656736.2025.2511031","DOIUrl":"10.1080/02656736.2025.2511031","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated whether radiofrequency hyperthermia (RFH) could enhance the effects of LTX-315, an oncolytic peptide, for hepatic cancer.</p><p><strong>Methods: </strong><i>In vitro</i> experiments using rat hepatocellular carcinoma (HCC) cells and <i>in vivo</i> experiments with HCC rat models were conducted. Treatments included (1) phosphate buffered saline, (2) RFH at 42 °C for 30 min, (3) LTX-315 alone, and (4) a combination of RFH with LTX-315. Cell viability and apoptosis were measured using MTS assay, flow cytometry, and fluorescence microscopy. Tumor growth was monitored for two weeks using ultrasound and optical imaging. The western blotting, enzyme-linked immunoassay, real-time polymerase chain reaction, were performed to detect the activation of cGAS-STING pathway. The immunohistochemistry, enzyme-linked immunoassay, real-time polymerase chain reaction, and flow cytometry analysis were performed to evaluate changes of immune cells in tumors, and changes of cytokines in plasma and tumors after the treatment.</p><p><strong>Results: </strong>The combination treatment (RFH + LTX-315) resulted in the highest level of apoptosis and the lowest cell viability, along with the smallest tumor volume and strongest reduction in bioluminescence signal compared to other groups (<i>p</i> < 0.001). LTX-315 activated the cGAS-STING pathway, with RFH further enhancing this activation. After combination therapy, significant increases in CD8+ T cells, CD8+/IFN-<i>γ</i>+ T cells, CD8+/TNF-<i>α</i>+ T cells, and natural killer cells, along with a decrease in Tregs, were observed in tumors (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>RFH significantly enhanced the effects of LTX-315 on orthotopic HCC by activating the cGAS-STING pathway.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2511031"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengths and weaknesses of transcranial ultrasound stimulation and its promise in psychiatry: an overview of the technology and a systematic review of the clinical applications.","authors":"David Attali, Maxime Daniel, Marion Plaze, Jean-François Aubry","doi":"10.1080/02656736.2025.2539986","DOIUrl":"10.1080/02656736.2025.2539986","url":null,"abstract":"<p><p>This article reviews early studies that have demonstrated the ability of low intensity ultrasound waves to modulate brain activity. It also reviews the technological developments that have enabled transcranial ultrasound stimulation (TUS) to achieve millimetric spatial accuracy. This allows precise, noninvasive and reversible brain stimulation, a unique capability when compared to existing techniques such as transcranial magnetic stimulation, transcranial direct-current stimulation, and deep brain stimulation with implanted electrodes. TUS is now technologically ready for clinical translation. As psychiatric disorders have a high prevalence in the general population, and suffer from unmet noninvasive deep brain stimulation clinical needs, this article focuses on the potential application of TUS in psychiatry and reviews recently published clinical proofs of concept that have addressed depression, anxiety, schizophrenia and substance use disorders. Finally, the strengths and weaknesses of TUS technology are discussed, with reference to its clinical translation.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2539986"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of the liver X receptor α protects the blood-brain barrier against heatstroke-induced injury.","authors":"Ping Li, Xiaoqian Liu, Xue Luo, Zhen Luo, Genlin He, Xuesen Yang","doi":"10.1080/02656736.2025.2559022","DOIUrl":"10.1080/02656736.2025.2559022","url":null,"abstract":"<p><strong>Background: </strong>Impairment of blood-brain barrier (BBB) contributes significantly to neuroinflammation and central nervous system (CNS) dysfunction in heatstroke. Our previous study revealed activation of liver X receptor α (LXRα) alleviates the heat stress-induced proinflammatory response in CNS; however, whether this protective effect is mediated by maintaining BBB integrity remains unknown. In this study, we focused on BBB integrity to explore the underlying mechanisms of LXRα in heatstroke.</p><p><strong>Methods: </strong>T0901317 (T0), an agonist of LXRα, was used to activate LXRα both <i>in vivo</i> and <i>in vitro</i>. Neurological deficits, neuroinflammation and BBB disruption were measured after mice were subjected to heatstroke. The BBB-mediated protective mechanism of LXRα activation in heatstroke was explored with brain microvascular endothelial cells <i>in vitro</i>.</p><p><strong>Results: </strong>Administration of T0 immediately after the onset of heatstroke significantly ameliorated heatstroke-induced neuroinflammation and neurological deficits. In addition, BBB leakage caused by heatstroke was alleviated by T0, and this protective effect was achieved by enhancing tight junctions in brain microvascular endothelial cells. Mechanistically, we found that expression of ATP-binding cassette transporter A1 (ABCA1) was increased after LXRα activation, whereas ABCA1 knockdown using esiRNAs abolished LXRα activation-mediated BBB preservation by suppressing the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) signaling pathway in brain microvascular endothelial cells.</p><p><strong>Conclusions: </strong>Our results indicated that LXRα activation could alleviate neuroinflammation and CNS dysfunction in heatstroke by maintaining BBB integrity, and relevant mechanisms may be related to JAK2/STAT3 signal activation via ABCA1. This research provide a novel strategy for managing heatstroke-associated BBB dysfunction.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2559022"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3.0-T closed MR-guided microwave ablation for HCC located under the hepatic dome: a single-center experience.","authors":"Kaihao Xu,&nbsp;Zhaonan Li,&nbsp;Chaoyan Wang,&nbsp;Chuan Tian,&nbsp;Dechao Jiao,&nbsp;Xinwei Han,&nbsp;Yan Yan","doi":"10.1080/02656736.2022.2107717","DOIUrl":"https://doi.org/10.1080/02656736.2022.2107717","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the clinical safety and efficacy of 3.0-T closed MR-guided microwave ablation (MWA) for the treatment of HCC located under the hepatic dome.</p><p><strong>Methods: </strong>From May 2018 to October 2020, 49 patients with 74 HCCs located under the hepatic dome underwent MWA using 3.0-T closed MR guidance. The technical success rate, operative time, complete ablation (CA) rate, complications, local tumor progression (LTP), tumor-free survival (TFS) and overall survival (OS) were examined. Routine blood analysis, liver/kidney function and alpha fetoprotein (AFP) and protein induced by vitamin k absent or antagonist (PIVKA) levels were compared before and 2 months after MWA.</p><p><strong>Results: </strong>All patients underwent MWA successfully, including 10 patients who underwent general anesthesia. The technical success rate was 100% without major complications. The CA rate was 95.9% (71/74) at the 2-month evaluation. The LTP rate was 2.7% during the median follow-up of 17.8 months (range: 4-43 months); the 6-, 12-, 18-month TFS rates were 97.8, 90.6, 68.1%, respectively, and the 6-, 12-, 18-month OS rates were 100, 97.6, 92.1%, respectively. There were no significant changes in routine blood tests and liver/kidney function (<i>p</i> > 0.05), while the AFP and PIVKA level decreased significantly at 2 months (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>3.0-T MR-guided MWA is safe and feasible for HCC lesions located under the hepatic dome.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":" ","pages":"1044-1051"},"PeriodicalIF":3.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40680164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of human tissue acoustic properties, abdominal wall shape, and respiratory motion on ultrasound-mediated hyperthermia for targeted drug delivery to pancreatic tumors.","authors":"Michael Gray,&nbsp;Laura Spiers,&nbsp;Constantin Coussios","doi":"10.1080/02656736.2022.2091799","DOIUrl":"https://doi.org/10.1080/02656736.2022.2091799","url":null,"abstract":"<p><strong>Background: </strong>PanDox is a Phase-1 trial of chemotherapeutic drug delivery to pancreatic tumors using ultrasound-mediated hyperthermia to release doxorubicin from thermally sensitive liposomes. This report describes trial-related hyperthermia simulations featuring: (i) new ultrasonic properties of human pancreatic tissues, (ii) abdomen deflections imposed by a water balloon, and (iii) respiration-driven organ motion.</p><p><strong>Methods: </strong>Pancreas heating simulations were carried out using three patient body models. Pancreas acoustic properties were varied between values found in the literature and those determined from our human tissue study. Acoustic beam distortion was assessed with and without balloon-induced abdomen deformation. Target heating was assessed for static, normal respiratory, and jet-ventilation-controlled pancreas motion.</p><p><strong>Results: </strong>Human pancreatic tumor attenuation is 63% of the literature values, so that pancreas treatments require commensurately higher input intensity to achieve adequate hyperthermia. Abdominal wall deformation decreased the peak field pressure by as much as 3.5 dB and refracted the focal spot by as much as 4.5 mm. These effects were thermally counteracted by sidelobe power deposition, so the net impact on achieving mild hyperthermia was small. Respiratory motion during moving beam hyperthermia produced localized regions overheated by more than 8.0 °C above the 4.0 °C volumetric goal. The use of jet ventilation reduced this excess to 0.7 °C and yielded temperature field uniformity that was nearly identical to having no respiratory motion.</p><p><strong>Conclusion: </strong>Realistic modeling of the ultrasonic propagation environment is critical to achieving adequate mild hyperthermia without the use of real time thermometry for targeted drug delivery in pancreatic cancer patients.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":" ","pages":"918-934"},"PeriodicalIF":3.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40628831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.","authors":"Yunhua Tan,&nbsp;Xin Wang,&nbsp;Kuansheng Ma,&nbsp;Lin Zhang,&nbsp;Jing Li,&nbsp;Ping Chen,&nbsp;Ben Zhang","doi":"10.1080/02656736.2021.2024279","DOIUrl":"https://doi.org/10.1080/02656736.2021.2024279","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the long-term efficacy of radiofrequency ablation (RFA) with a multiple-electrode switching system (MESS) in the treatment of early hepatocellular carcinoma (HCC) and evaluate the patterns and risk factors of intrahepatic recurrence of HCC after RFA.</p><p><strong>Methods: </strong>In total, 139 patients with early HCC who underwent RFA with MESS as primary treatment at multiple centers were prospectively enrolled according to the inclusion criteria. We evaluated the local tumor progression (LTP), intrahepatic distant recurrence (IDR), the incidence of cumulative disease-free survival (DFS), LTP-free survival, IDR-free survival, and overall survival. We also analyzed the associated risk factors.</p><p><strong>Results: </strong>A total of 139 patients were included in the study and the median follow-up time was 64 months, ranging from 11 to 72 months. The complete ablation rate was 98.56%. Sixty-nine (49.64%) were found to have intrahepatic recurrence (LTP, <i>n</i> = 15; IDR, <i>n</i> = 55) during follow-up. The 1-year, 3-year and 5-year cumulative DFS, LTP-free survival, and IDR-free survival rates were 74.82, 94.46 and 78.75%; 54.68, 88.03 and 61.79%; and 51.80, 85.67 and 60.17%, respectively. In the multivariable analysis, tumor size > 4 cm was the only important risk factor for LTP. The alkaline phosphatase (ALP) level and the number of tumors were independent risk factors for IDR; α-fetoprotein (AFP) level > 400 µg/L and recurrence interval were risk factors for the overall survival period.</p><p><strong>Conclusions: </strong>The MESS-RFA is an effective method for local control of tumors in early HCC. Early HCC with multiple high-ALP tumors has a higher rate of recurrence, which mainly occurs in an IDR pattern. Early HCC with high AFP levels and a shorter initial recurrence interval resulted in a poorer prognosis. Thus, treatments such as liver transplantation or surgical resection may be a good strategy in those cases.</p><p><strong>Clinicaltrials.gov id: </strong>NCT02046356.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":" ","pages":"190-199"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39706943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}